We spoke with Dr. Folasade May, Co-Leader of the SU2C Colorectal Cancer Health Equity Dream Team, about the importance of screenings, why we are reluctant, and how we can overcome our fears.

Kelly Spill had bloody stool during pregnancy and figured it was due to hemorrhoids. When her son was 8 months old, she was diagnosed with stage 3 colorectal cancer.

Colorectal cancer remains a significant health concern, particularly for the Black community, which faces higher incidence rates and lower survival rates compared to the white population.

When Sascha Roth of Northwest D.C. noticed bleeding as she went to the bathroom, she initially shrugged it off. She would later be diagnosed with Stage 3 rectal cancer.

A conversation with Stand Up To Cancer researcher Chanita Hughes-Halbert, Ph.D., and grant recipient Triage Cancer co-founder and COO Monica Fawzy Bryant, Esq.

Colon cancer symptoms often don’t exist. An active woman shares how repeated nudges from a loved one led to her diagnosis: “My entire life changed that day.”

Stand Up To Cancer® announced changes to its Scientific Advisory Committee (SAC), which oversees SU2C’s scientific research.

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

AbbVie is leading branded drug ad spending this year with Skyrizi at $415 million through the first nine months of the year, according to Vivvix data. Sanofi and Regeneron’s Dupixent is in second at $369 million, but another AbbVie brand, Rinvoq, is a close third with $357 million spent so far, according to the MediaRadar company, with paid social data from Pathmatics.

Stand Up To Cancer® (SU2C) today announced the appointment of Julian Adams, Ph.D., as president and chief executive officer, which will be effective on January 1, 2024. Adams had previously served on SU2C’s Scientific Advisory Committee since 2008, and officially joined SU2C in July 2023 in the newly created position of chief science officer.